# Hypoxic Changes in Hepatocellular Carcinoma (HCC) Following Trans Arterial Chemo Embolization and Stereotactic Radiation: Fluorine18 (18F) Fluoromisonidazole (FMISO) Imaging

> **NCT03303469** · PHASE2 · TERMINATED · sponsor: **University of Alabama at Birmingham** · enrollment: 3 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** FMISO
- **DRUG:** FMISO
- **DRUG:** FMISO

## Key facts

- **NCT ID:** NCT03303469
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-10-30
- **Primary completion:** 2021-01-06
- **Final completion:** 2021-01-06
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** study was terminated due to poor enrollment
- **Last updated:** 2021-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03303469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03303469, "Hypoxic Changes in Hepatocellular Carcinoma (HCC) Following Trans Arterial Chemo Embolization and Stereotactic Radiation: Fluorine18 (18F) Fluoromisonidazole (FMISO) Imaging". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03303469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*